Effectiveness of Regdanvimab at Preventing the Need for Oxygen Therapy in Patients with Mild-to-Moderate COVID-19: A Retrospective Cohort Study

BACKGROUND: Monoclonal antibodies are a treatment option for patients with mild-to-moderate coronavirus disease (COVID-19). We investigated the effectiveness of regdanvimab, an anti-severe acute respiratory syndrome coronavirus-2 monoclonal antibody approved in Korea, in the treatment of patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Seong Jin, Park, Sang-Won, Lee, Eunyoung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Infectious Diseases; Korean Society for Antimicrobial Therapy; The Korean Society for AIDS 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987185/
https://www.ncbi.nlm.nih.gov/pubmed/35384421
http://dx.doi.org/10.3947/ic.2021.0140

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987185/
https://www.ncbi.nlm.nih.gov/pubmed/35384421
http://dx.doi.org/10.3947/ic.2021.0140

Ejemplares similares